Stephen R. Wedge

10.8k citations

103 papers · 7.0k indexed · 3 hit papers · h-index 39

Impact in

Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism
Genetics top 0.5%
- Glioma Diagnosis and Treatment

Papers in

Cancer Research 26
- Cancer, Hypoxia, and Metabolism 24
Oncology 44
- Cancer-related Molecular Pathways 9
- Cancer Treatment and Pharmacology 8

Co-authors: Jane Kendrew E.S. Newlands Ian J. Stratford C. Brock Richard T. Wheelhouse M. F. G. STEVENS Laurent Hennequin Jon Curwen
Journals: British Journal of Cancer (13 papers)Cancer Research (11 papers)Molecular Cancer Therapeutics (8 papers)Clinical Cancer Research (6 papers)Journal of Medicinal Chemistry (4 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Stephen R. Wedge

102 papers receiving 6.8k citations

Hit Papers

align trajectories log scale

Guidelines for the welfare and use of animals in cancer research 2010 · 1.1k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 British Journal of Cancer
2002 PubMed
1997 Cancer Treatment Reviews

Peers

Countries citing papers authored by Stephen R. Wedge

Since Specialization

Citations

This map shows the geographic impact of Stephen R. Wedge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen R. Wedge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen R. Wedge more than expected).

Fields of papers citing papers by Stephen R. Wedge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen R. Wedge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen R. Wedge. The network helps show where Stephen R. Wedge may publish in the future.

Co-authors

The 25 scholars most cited alongside Stephen R. Wedge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen R. Wedge Line = papers co-authored together Stephen R. Wedge links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy Journal of Medicinal Chemistry ·Duncan C. Miller, Suzannah J. Harnor, Mathew P. Martin, Richard A. Noble, Stephen R. Wedge, Céline Cano	2023	15
2	Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach Organic & Biomolecular Chemistry ·Duncan C. Miller, Mathew P. Martin, Santosh Adhikari, Alfie Brennan, Jane Endicott, Bernard T. Golding, Ian R. Hardcastle, Amy B. Heptinstall, Stephen J. Hobson, Claire Jennings, Lauren Molyneux, Yvonne Ng, Stephen R. Wedge, M.E.M. Noble, Céline Cano	2018	12
3	Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib Scientific Reports ·Sonia M Novo, Stephen R. Wedge, Lesley A. Stark	2017	4
4	Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma Haematologica ·Richard A. Noble, Natalie Bell, Helen J. Blair, Arti Sikka, Huw D. Thomas, Nicole Phillips, Sirintra Nakjang, Satomi Miwa, Rachel E. Crossland, Vikki Rand, Despina Televantou, Anna Long, Hector C. Keun, Chris M. Bacon, Simon Bomken, Susan E. Critchlow, Stephen R. Wedge	2017	119
5	Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Clinical Cancer Research ·Neil R. Smith, Dawn Baker, Matthew R. Farren, Aurélien Pommier, Ruth Swann, Xin Wang, Sunita Mistry, Karen McDaid, Jane Kendrew, Chris Womack, Stephen R. Wedge, Simon T. Barry	2013	111
6	Examining Changes in [18 F]FDG and [18 F]FLT Uptake in U87-MG Glioma Xenografts as Early Response Biomarkers to Treatment with the Dual mTOR1/2 Inhibitor AZD8055 Molecular Imaging and Biology ·Heather Keen, Sally‐Ann Ricketts, Juliana Maynard, Armelle Logié, Rajesh Odedra, Aoife M. Shannon, Stephen R. Wedge, Sylvie M. Guichard	2013	14
7	Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft Molecular Cancer Therapeutics ·Joana M. Senra, Brian A. Telfer, Kim E. Cherry, Cian M. McCrudden, David G. Hirst, Mark J. O’Connor, Stephen R. Wedge, Ian J. Stratford	2011	155
8	Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family Molecular Cancer Therapeutics ·Sandra R. Brave, Kirsty Ratcliffe, Zena Wilson, Neil H. James, Sue Ashton, Anna Wainwright, Jane Kendrew, Philippa Dudley, Nicola Broadbent, Graham Sproat, Sian Taylor, Claire H. Barnes, Jeffrey C. Silva, Charles L. Farnsworth, Laurent Hennequin, Donald Ogilvie, Juliane M. Jürgensmeier, Masabumi Shibuya, Stephen R. Wedge, Simon T. Barry	2011	72
9	The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts Clinical Cancer Research ·Aoife M. Shannon, Brian A. Telfer, Paul D. Smith, Muhammed Babur, Armelle Logié, Robert W. Wilkinson, Camille Debray, Ian J. Stratford, Kaye J. Williams, Stephen R. Wedge	2009	42
10	Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: Selective inhibitors of Aurora B kinase with potent anti-tumor activity Bioorganic & Medicinal Chemistry Letters ·Kevin M. Foote, Andrew Mortlock, Nicola M. Heron, Frédéric Jung, George B. Hill, Georges Pasquet, Madeleine C. Brady, Stephen Green, Simon P. Heaton, Sarah Kearney, Nicholas Keen, Rajesh Odedra, Stephen R. Wedge, Robert W. Wilkinson	2008	32
11	Examining inhibition of VEGFR and EGFR signaling in MMTV-neu transgenic mice with well-established tumors: an immunohistochemical and oncogenomic analysis of AZD2171, vandetanib and gefitinib treatment Cancer Research ·Stephen R. Wedge, Teresa Klinowska, Neil R. Smith, Helen Brown, Paul Farrington, Kai‐Ming Chang, Marie C. South, Alex Graham, Lynsey Womersley, Peter A. Hall, Sharon Barnett, Donald Ogilvie	2007	1
12	Inhibition of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171 Cancer Research ·Caroline A. Heckman, Tanja Holopainen, Maria Wirzenius, Salla Keskitalo, Michael Jeltsch, Stephen R. Wedge, Juliane M. Jürgensmeier	2007	1
13	AZD1152: A highly potent and specific aurora kinase inhibitor. Cancer Research ·Robert W. Wilkinson, Nicholas Keen, Rajesh Odedra, Simon P. Heaton, Stephen R. Wedge, Kevin M. Foote, Andrew Mortlock, Frédéric Jung, Nicola M. Heron, Madeleine C. Brady, Mike Walker, Liz Khatri, Nigel Barrass, J. J. Foster, Stephen Green	2006	6
14	Inhibition of VEGFR reduces polyp burden in the APC (min/+) mouse model of intestinal cancer Gut ·Denis Alférez, Robert A. Goodlad, J Watkins, Richard Poulsom, Anderson J. Ryan, Stephen R. Wedge, Ian Pyrah, Nikki Mandir, R W Wilkinson	2006	1
15	Oral Presentations 5 British Journal of Cancer ·Hsiao-Wee Chng, Richard S. Camplejohn, Ian R. Hart, Louise Nicholson, Robert W. Wilkinson, Anderson J. Ryan, Stephen R. Wedge, Itg Pyrah, Nikki Mandir, Robert A. Goodlad, K Lankester, R. J. Maxwell, RB Pedley, Stephen Hill, G.J.S. Rustin, Gillian M. Tozer, Zhaohua Gao, Ying Zhu, Bin-Hui Wang, D Yu	2004	1
16	The VEGF receptor tyrosine kinase inhibitor AZD2171 inhibits VEGF signaling, angiogenesis, and tumor growth in vivo Cancer Research ·Stephen R. Wedge, Jane Kendrew, Paula J. Valentine, Lyndsey L. Kilburn, Jon Curwen, Helen Musgrove, Martine J. Mellor, Sharon Barnett, P.F. Wadsworth, Graham H.P. Richmond, Alison Bigley, Laurent Hennequin, Patrick A. Plé, Elaine S. E. Stokes, Donald Ogilvie	2004	7
17	ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor-Receptor-2 Tyrosine Kinase Activity Microcirculation ·C.E. Whittles, Tristan Pocock, Stephen R. Wedge, Jane Kendrew, Laurent Hennequin, SJ Harper, David O. Bates	2002	5
18	Phase I trial of temozolomide using an extended continuous oral schedule. PubMed ·C. Brock, E.S. Newlands, Stephen R. Wedge, Mark Bower, Helen Evans, Iain Colquhoun, Mary E. Roddie, M.G. Glaser, MH Brampton, Gordon Rustin	1998	228
19	Effect of single and multiple administration of an O ? 6 -benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model Cancer Chemotherapy and Pharmacology ·Stephen R. Wedge, Julia K. Porteous, E.S. Newlands	1997	52
20	Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol) in human plasma and urine by high-performance liquid chromatography Journal of Chromatography B Biomedical Sciences and Applications ·Stephen R. Wedge, Sudsawat Laohavinij, G. A. Taylor, David R. Newell	1995	5

About Stephen R. Wedge

Stephen R. Wedge is a scholar working on Cancer Research, Oncology, Molecular Biology, Genetics and Pulmonary and Respiratory Medicine, having authored 103 papers that have together received 7.0k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (34 papers), Cancer, Hypoxia, and Metabolism (24 papers), PI3K/AKT/mTOR signaling in cancer (13 papers), Glioma Diagnosis and Treatment (10 papers), Cancer-related Molecular Pathways (9 papers), Lung Cancer Treatments and Mutations (9 papers), Cancer Treatment and Pharmacology (8 papers) and Microtubule and mitosis dynamics (8 papers). The work is most often cited by research in Cancer Research (1.4k citations), Genetics (1.0k citations), Oncology (2.6k citations), Molecular Biology (3.6k citations) and Pulmonary and Respiratory Medicine (1.6k citations). Stephen R. Wedge has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Jane Kendrew, E.S. Newlands, Ian J. Stratford, C. Brock, Richard T. Wheelhouse, M. F. G. STEVENS, Laurent Hennequin, Jon Curwen, Donald Ogilvie and Elaine S. E. Stokes. Their work appears in journals such as British Journal of Cancer, Cancer Research, Molecular Cancer Therapeutics, Clinical Cancer Research and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact